Rubbish Check
Daily Mail Money · 3 August 2026
source“AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger”
R2/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates the Daily Mail's claim that AstraZeneca and Bristol Myers Squibb "holds talks" over a £300bn merger a 2/10, because the headline is a near-direct currency-converted echo of the Financial Times' own original report, and the body faithfully carries the caveats that the deal "may be delayed or fall apart."
The Verdict
Lightly altered. This is about as close to the base fact as a headline gets: the FT broke the story with a nearly identical headline in dollars, and the Daily Mail's £300bn framing tracks the reported ~$400bn combined value once converted. The one deduction is for stating "holds talks" without an "reportedly" qualifier in the headline itself, even though the article body immediately hedges with FT's own uncertainty language.
What actually happened
The Financial Times reported that AstraZeneca and Bristol Myers Squibb have held merger discussions in recent months that could create the world's fourth-largest drugmaker. Other outlets corroborated the same FT report, with the deal valued at roughly $400 billion combined and AstraZeneca shares dropping sharply on the news. Neither company confirmed the talks, and multiple outlets noted the negotiations might not result in an agreement.
Key facts
- CNBC confirmed the FT reported the megadeal talks would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
- Axios reported AstraZeneca shares fell more than 6% in London on the news, while Bristol-Myers stock was up around 4% at the open in New York, matching the article's cited 6.81% drop to 11,772.00p.
- AstraZeneca's own scale check: Before Monday's session, AstraZeneca's market capitalization stood at $264 billion, against the article's £196bn figure and BMS's roughly £133bn.
- Analysts were skeptical of the strategic logic: Jefferies wrote "Given the strength of AZ's growth and innovation profile, we are a bit perplexed. If there is one company that doesn't need financial engineering, it's AZ."
- Deal uncertainty was flagged industry-wide: talks may not lead to deal, per Endpoints News's summary of the same report.
What to watch for
Watch whether AstraZeneca or BMS issue any formal confirmation or denial, since neither had responded to press inquiries at time of the original reports. The oncology-portfolio overlap flagged by Jefferies is the likeliest trigger for antitrust scrutiny if talks progress, and Soriot's public insistence that AZ doesn't "need M&A" is worth revisiting if a deal does materialise.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
Related
